General
Preferred name
BRICICLIB
Synonyms
ON 014185 ()
BRICICLIB SODIUM ()
ON-014185 ()
ON-013105 ()
ON014185 ()
ON 013105 ()
ON013105 ()
P&D ID
PD058742
CAS
865783-99-9
865784-01-6
Tags
available
drug candidate
Drug indication
Solid tumour/cancer
Drug Status
investigational
Max Phase
1.0
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Briciclib, also known as ON 013105 or ON 014185, is a benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity. Upon hydrolysis, cyclin D modulator ON 013105 is converted to ON 013100, which blocks cyclin D mRNA translation and decreases protein expression of cyclin D. This may induce cell cycle arrest and apoptosis in cancer cells overexpressing cyclin D and eventually decrease tumor cell proliferation. This agent may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. Cyclin D, a member of the cyclin family of cell cycle regulators, plays a key role in cell cycle division and is often overexpressed in a variety of hematologic and solid tumors and is correlated with poor prognosis.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Briciclib is a small molecule that suppresses cyclin D1 accumulation in cancer cells. It is a benzyl styryl sulfone analog, and a disodium phosphate ester prodrug of ON 013100, with potential antineoplastic activity. It may exhibit synergistic antitumor activity in combination with other chemotherapeutic agents. It inhibits the proliferation of MCL, gastric, breast and esophageal cancer cell lines at nanomolar concentrations (GI50 = 9.8 - 12.2 nM) in vitro. It binds to eIF4E, blocking cap-dependent translation of cyclin D1 and other cancer proteins and leads to tumor cell death in vitro. It is active in nonclinical tumor models when combined with several chemotherapeutics.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
12
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugMAP
JUMP-Target 1 Compound Set
MedChem Express Bioactive Compound Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
23
Molecular Weight
474.07
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
2
Rotatable Bonds
10
Ring Count
2
Aromatic Ring Count
2
cLogP
2.78
TPSA
137.82
Fraction CSP3
0.26
Chiral centers
0.0
Largest ring
6.0
QED
0.49
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Cell Cycle/Checkpoint
Autophagy
Cell Cycle/DNA Damage
Target
cyclin D1
CCND1
Eukaryotic Initiation Factor (eIF)
eIF
MOA
cyclin D inhibitor
Solubility
DMSO: > 31 mg/mL
Source data
